Immunome, Inc. (IMNM) Revenue History
Annual and quarterly revenue from 2018 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
IMNM Revenue Analysis (2018–2024)
As of March 1, 2026, Immunome, Inc. (IMNM) generated trailing twelve-month (TTM) revenue of $9.7 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q3 2025) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, IMNM's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $14.0 million in 2023.
When compared to Healthcare sector peers including REGN (+1.0% YoY), CLDX (-78.6% YoY), and RXRX (+27.5% YoY), IMNM has underperformed the peer group in terms of revenue growth. Compare IMNM vs REGN →
Peer Comparison
Compare IMNM's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IMNMCurrent | $10M | -100.0% | - | -3382.4% | |
| REGN | $14.3B | +1.0% | +11.0% | 25.7% | |
| CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
| RXRX | $75M | +27.5% | +85.4% | -867.9% | |
| NRIX | $84M | +54.0% | +36.3% | -340.2% | |
| ROIV | $29M | -56.4% | -15.6% | -3453.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $9.0M | -35.5% | $9.0M | 100.0% | $-305,800,000 | -3382.4% |
| 2023 | $14.0M | - | $14.0M | 100.0% | $-109,530,000 | -781.4% |
| 2022 | $0 | - | $0 | - | $-36,901,000 | - |
| 2021 | $0 | - | $0 | - | $-25,204,000 | - |
| 2020 | $0 | - | $-755,000 | - | $-12,261,000 | - |
| 2019 | $0 | - | $-615,000 | - | $-10,348,000 | - |
| 2018 | $0 | - | $-521,000 | - | $-7,743,000 | - |
See IMNM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IMNM Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare IMNM vs AGIO
See how IMNM stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is IMNM's revenue growth accelerating or slowing?
IMNM revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $10M. This reverses the prior growth trend.
What is IMNM's long-term revenue growth rate?
Immunome, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is IMNM's revenue distributed by segment?
IMNM reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2024 are available for download. Segment mix reveals concentration and diversification trends.